ArticleAmerican journal of translational research2021
Influences of Jieyu Ruanjian Huoxue prescription on hepatic fibrosis indices and APRI in patients with hepatitis B cirrhosis.
Article in American journal of translational research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the influences of Jieyu Ruanjian Huoxue prescription on hepatic fibrosis indices and aspartate aminotransferase to platelet ratio index (APRI) in patients with hepatitis B cirrhosis (HBC).
methodsA total of 140 patients with hepatitis B complicated with cirrhosis who received treatment in our hospital from January 2019 to December 2019 were selected as the research subjects. and Accoridng to the difference of intervention methods, the patients were divided into the study group (n=80, conventional treatment combined with Jieyu Ruanjian Huoxue prescription) and the control group (n=60, conventional treatment). The clinical intervention effects, changes in hepatic fibrosis indices and hepatic function indices, and levels of inflammatory factors before and after intervention were analyzed. In addition, Pearson correlation analysis was conducted to analyze the correlation between fibrosis indices and hepatic function indices in patients with HBC.
resultsThe overall response rate in the study group was markedly higher than that in the control group (98.75% vs. 91.67%,
conclusionJieyu Ruanjian Huoxue prescription can remarkably improve the hepatic fibrosis, abnormal hepatic function, and the level of inflammatory factors in patients with HBC, exhibiting a satisfactory efficacy. Therefore, Jieyu Ruanjian Huoxue prescription is worthy of clinical promotion and implementation.
Indexed as
Identifiers
34377349PMC8340173W3187433805What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.